Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.61 |
| ▸ | PI4KA | P42356 | 3/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 6/20 | 0.50 |
| ▸ | HCK | P08631 | 6/20 | 0.50 |
| ▸ | SRC | P12931 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.50 |
| ▸ | MTOR | P42345 | 6/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.50 |
| ▸ | PRKDC | P78527 | 6/20 | 0.50 |
| ▸ | XDH | P47989 | 5/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179551 | 0.83 | PI4KB (0.54) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL15627374 | 0.83 | PI4KB (0.54) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL23059282 | 0.83 | PI4KB (0.54) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL243654 | 0.83 | PI4KB (0.54) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL850318 | 0.80 | GSK3B (0.39) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL24393328 | 0.80 | GSK3B (0.39) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL15079234 | 0.79 | KDM4E (0.40) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL839258 | 0.79 | GSK3B (0.38) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL25590056 | 0.79 | GSK3B (0.38) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| SCHEMBL11617335 | 0.77 | SMN1; SMN2 (0.41) | PI4KBPI4KAPI4K2BPI4K2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117866991-A | Chimeric antigen receptor for the treatment of cancer | 诺华股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-110225927-B | Chimeric antigen receptor for the treatment of cancer | 诺华股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7626014-B2 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | PI4KB 468/4885PI4KA 418/4885PI4K2B 748/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | PI4KB 497/4885PI4KA 1248/4885PI4K2B 1529/4885 |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | PI4KB 496/4885PI4KA 645/4885PI4K2B 920/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | PI4KB 434/4885PI4KA 643/4885PI4K2B 632/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | PI4KB 3263/4885PI4KA 3570/4885PI4K2B 3711/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | PI4KB 2017/4885PI4KA 2231/4885PI4K2B 2181/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | PI4KB 1913/4885PI4KA 2780/4885PI4K2B 2783/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | PI4KB 1821/4885PI4KA 2565/4885PI4K2B 2467/4885 |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | PI4KB 468/4885PI4KA 418/4885PI4K2B 748/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | PI4KB 1597/4885PI4KA 1930/4885PI4K2B 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.